EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep

Toloo Taghian, Jillian Gallagher, Stephanie Bertrand, William C Baker, Kalajan Lopez Mercado, Hector R Benatti, Erin Hall, Yvette Lopez, Abigail McElroy, John T McCarthy, Sanjana Pulaparthi, Deborah Fernau und 25 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci182942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Toloo Taghian und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Tay-Sachs Disease, beta-Hexosaminidase alpha Chain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIDDK NIH HHS, National Tay-Sachs and Allied Diseases Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tay-Sachs disease (TSD) and Sandhoff disease are fatal neurodegenerative diseases without an effective therapy that are caused by mutations in the HEXA and HEXB genes, respectively. Together they encode the heterodimeric isozyme of hexosaminidase, hexosaminidase A (HexA), that degrades GM2 ganglioside. This report describes a 5-year-long study using a bidirectional adeno-associated virus 9 (AAV9) vector (AAV9-Bic_HexA/HexB) encoding both HEXA and HEXB in the TSD sheep model. Bidirectional AAV9 was delivered i.v. or through various cerebrospinal fluid (CSF) delivery routes: intracerebroventricular (ICV), cisterna magna (CM), and lumbar intrathecal space (LIT). The longest survival and best distribution were achieved by multipoint CSF delivery (combined CM, ICV, and LIT) with treated animals that survived up to 5 years of age (untreated animals with TSD die after ~9 months). Extension in survival was accompanied by lasting improvement in neurological examination and maze testing. Improvement in biomarkers of efficacy, including MRI, magnetic resonance spectroscopy, diffusion tensor imaging, and CSF levels of GM2 ganglioside and HexA activity, was evident. Postmortem assessments showed broad HexA distribution, GM2 ganglioside clearance, and vector genome distribution, especially in deep brain structures. Therapeutic efficacy documented in this study supports translation of bidirectional vector and multipoint CSF delivery to a clinical trial in patients with TSD and Sandhoff disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyDependovirusTay-Sachs Diseasebeta-Hexosaminidase alpha ChainHexosaminidase AAnimalsSheepGenetic VectorsHumansDisease Models, AnimalG(M2) Gangliosidebeta-Hexosaminidase beta Chain

Stichwörter der Autor:innen

DevelopmentGene therapyLysosomesNeurological disordersTherapeutics

Substanzen

beta-Hexosaminidase alpha ChainG(M2) GangliosideHexosaminidase Abeta-Hexosaminidase beta Chain

Autor:innen und Institutionen

  • Department of Radiology and.
  • Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Tufts Farm, Cummings College of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA.
  • Scott-Ritchey Research Center, Auburn University College of Veterinary Medicine, Auburn, Alabama, USA.
  • Department of Medicine, Washington University, St. Louis, Missouri, USA.
  • Department of Clinical Sciences.

Förderung

  • NINDS NIH HHS
  • NIDDK NIH HHS
  • National Tay-Sachs and Allied Diseases Association
  • UMass Chan Medical School
  • Scott-Ritchey Research Center
  • NIH

Zitieren

APA

Taghian, T., Gallagher, J., Bertrand, S., Baker, W. C., Lopez Mercado, K., Benatti, H. R., Hall, E., Lopez, Y., McElroy, A., McCarthy, J. T., Pulaparthi, S., Fernau, D., Mather, S., Esteves, S., Diffie, E., Gross, A., Lahey, H. G., Jiang, X., Parsley, E., …, & Gray-Edwards, H. (2025). Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep. Journal of Clinical Investigation. https://doi.org/10.1172/jci182942

Vancouver

Taghian T, Gallagher J, Bertrand S, Baker WC, Lopez Mercado K, Benatti HR, et al. Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep. Journal of Clinical Investigation. 2025. doi:10.1172/jci182942

BibTeX
@article{Taghian2025,
  author = {Taghian, Toloo and Gallagher, Jillian and Bertrand, Stephanie and Baker, William C and Lopez Mercado, Kalajan and Benatti, Hector R and Hall, Erin and Lopez, Yvette and McElroy, Abigail and McCarthy, John T and Pulaparthi, Sanjana and Fernau, Deborah and Mather, Samuel and Esteves, Sophia and Diffie, Elise and Gross, Amanda and Lahey, Hannah G and Jiang, Xuntian and Parsley, Elizabeth and Gately, Rachael and Prestigiacomo, Rachel and Johnson, Siauna and Taylor, Amanda and Bierfeldt, Lindsey and Tuominen, Susan and Koehler, Jennifer and Gao, Guangping and Xie, Jun and Su, Qin and King, Robert and Gounis, Matthew J and Anagnostakou, Vania and Puri, Ajit and Batista, Ana Rita and Sena-Esteves, Miguel and Martin, Douglas R and Gray-Edwards, Heather},
  title = {Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci182942}
}
Kostenlos starten →